-+ 0.00%
-+ 0.00%
-+ 0.00%

Sagimet plans US Phase 3 denifanstat acne trial start in H2 2026

PUBT·04/27/2026 11:06:22
Listen to the news
Sagimet plans US Phase 3 denifanstat acne trial start in H2 2026
  • Sagimet shifted capital focus to dermatology, planning a US Phase 3 trial of once-daily oral denifanstat in moderate to severe acne in 2H 2026, subject to IND clearance.
  • Positive topline results were already reported from an open-label Phase 3 long-term safety study of denifanstat in China, showing it was generally well tolerated and supported improvements across measured efficacy outcomes.
  • Development of FASN inhibitor TVB-3567 continued in a first-in-human Phase 1 trial, with Phase 2 in acne targeted for 2H 2026.
  • MASH program for denifanstat plus resmetirom was positioned as Phase 2-ready in 2H 2026, with further clinical work deferred until non-dilutive funding is secured.
  • Sagimet scheduled a KOL webcast for April 30, 2026 to outline its acne development strategy for denifanstat.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270700PRIMZONEFULLFEED9707243) on April 27, 2026, and is solely responsible for the information contained therein.